Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

77 projects found matching your search criteria :

  1. Genetic factors influencing response to immunotherapy and prognosis in patients with melanoma brain metastases

    Call: PRELUDIUM 24 , Panel: NZ2

    Principal investigator: Piotr Jan Błoński

    Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie

  2. Strategy to overcome the "ionic checkpoint" and improve the antitumor immunotherapy.

    Call: OPUS 29 , Panel: NZ7

    Principal investigator: dr Beata Pyrzyńska

    Warszawski Uniwersytet Medyczny

  3. M. bovis BCG extracellular vesicles as an alternative in bladder cancer immunotherapy

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Jakub Smoliński

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

  4. Dual cell cycle blockade and immune checkpoint inhibition as a potential strategy of sequential anticancer therapy

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Alicja Stanisława Słota

    Uniwersytet Jagielloński

  5. LLT1 as a regulator of the immune response and a dual-target immunotherapy approach in colorectal cancer directed at NK ...

    Call: OPUS 29 , Panel: NZ6

    Principal investigator: dr Marzena Dorota Lenart

    Uniwersytet Jagielloński

  6. Next-Generation Exosome Therapy: Engineering NK Cell-Derived Vesicles for Targeted Cancer Treatment

    Call: SONATINA 9 , Panel: NZ6

    Principal investigator: dr Daria Nawrocka

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

  7. New Horizons in Cancer Immunotherapy: Blocking LAG-3/FGL1 Interactions

    Call: SONATA 20 , Panel: NZ7

    Principal investigator: dr Jacek Plewka

    Uniwersytet Jagielloński

  8. Novel insights into inhibition of PD-L1/PD-1 immune checkpoint – discovery and optimization of covalent PD-L1 inhibitors...

    Call: SONATA 20 , Panel: ST5

    Principal investigator: dr Radosław Dariusz Kitel

    Uniwersytet Jagielloński

  9. Investigation of the mechanism of enhanced liposome delivery to tumors and its application for dual target immunotherapy

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Piotr Rygiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  10. Neutrophil Dynamics: Unveiling Anti-Tumor and Therapy Efficacy with the TUmor Neutrophil Immunotherapy on Chip (TUNIC) m...

    Call: SONATA 20 , Panel: NZ6

    Principal investigator: dr Martin Nurmik

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  11. Harnessing NK cells and Graphene Oxide Nanoparticles for Pancreatic Ductal Adenocarcinoma Immunotherapy

    Call: OPUS 28 (LAP) , Panel: NZ7

    Principal investigator: prof. Iwona Maria Inkielewicz-Stępniak

    Gdański Uniwersytet Medyczny

  12. Small molecule modulators of the tumor necrosis factor alpha signaling pathway for the inhibition of inflammatory proces...

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: prof. Tadeusz Holak

    Uniwersytet Gdański

  13. Innovative Small Molecule Inhibitors Targeting LAG-3 and MHCII Complex for Tumour Immunotherapy

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr Jacek Plewka

    Uniwersytet Jagielloński

  14. Neutrophil-targeted immune response as an effective approach in immunotherapyof gastrointestinal cancers

    Call: OPUS 27 , Panel: NZ5

    Principal investigator: dr Damian Jacenik

    Uniwersytet Łódzki

  15. Controlling the covalent activity of a PD-L1 inhibitors with light

    Call: PRELUDIUM 23 , Panel: NZ7

    Principal investigator: Wiktor Jan Uzar

    Uniwersytet Jagielloński

  16. CAR(dio)-T(oxicity)- Engineered Heart Tissue model for CAR-T cardiotoxicity evaluation

    Call: SONATA 19 , Panel: NZ7

    Principal investigator: dr Agnieszka Joanna Zimna

    Instytut Genetyki Człowieka PAN

  17. Modulation of the N-glycosylation as a tool to improve the CAR-T immunotherapy efficacy

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr Agnieszka Graczyk-Jarzynka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  18. Increasing sensitivity to immunotherapy in lung cancer via immunostimulation and modulation of tumor microenvironment

    Call: SONATA BIS 13 , Panel: NZ5

    Principal investigator: dr Urszula Oleksiewicz

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  19. Exploring kinase hyperactivation as an innovative approach for chemo-immunotherapy for B cell acute lymphoblastic leukem...

    Call: PRELUDIUM BIS 5 , Panel: NZ7

    Principal investigator: dr hab. Małgorzata Firczuk

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  20. Strategies to improve the efficacy of NK cells in targeting aggressive B-cell lymphomas

    Call: WEAVE-UNISONO , Panel: NZ6

    Principal investigator: dr Małgorzata Bobrowicz

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  21. Searching for novel regulators of antitumor immune response

    Call: MAESTRO 15 , Panel: NZ6

    Principal investigator: dr hab. Magdalena Hanna Winiarska

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  22. Assessment of the potential development of novel antibody fragments targeting IL13Rα2 using the phage display technique ...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Justyna Katarzyna Jureczek

    Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej

  23. Unraveling protease activation in stimulated CAR-T cells to identify new biomarkers for assessing their clinical efficac...

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: dr hab. Małgorzata Firczuk

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  24. Heterogeneity immunocompetent cells during chimeric antigen receptor T cell (CAR-T) CD19 immunotherapy.

    Call: PRELUDIUM 22 , Panel: NZ6

    Principal investigator: Aleksandra Maria Oszer

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  25. Targeting undruggable proteins involved in tumorigenesis – developing and characterization of advanced nanoplatform for ...

    Call: OPUS 25 , Panel: NZ6

    Principal investigator: dr hab. Monika Bzowska

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Bitechnologii

  26. Spatial Determinants of Immunotherapy Resistance in Cancer

    Call: WEAVE-UNISONO , Panel: NZ6

    Principal investigator: dr Marcin Tabaka

    Instytut Chemii Fizycznej Polskiej Akademii Nauk, Międzynarodowe Centrum Badań Oka

  27. Development of novel anti-cancer immunotherapy against mesothelioma comprising of oncolytic adenovirus vectors armed wit...

    Call: SONATA 18 , Panel: NZ7

    Principal investigator: dr Łukasz Kuryk

    Narodowy Instytut Zdrowia Publicznego - Państwowy Zakład Higieny (NIZP - PZH)

  28. A smart stride for cancer: synergistic effect of co-delivery chemo- andphototherapeutic agents using magneto-fluorescent...

    Call: POLONEZ BIS 2 , Panel: NZ7

    Principal investigator: dr Prachi Uttam Ghoderao

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  29. CO-TARGETING OF TUMOR MICROENVIRONMENT-MEDIATED ADAPTATION TO HYPOXIA RENDERS GLIOBLASTOMA MORE SUSCEPTIBLE TO ONCOLYTIC...

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr hab. Agnieszka Marta Bronisz

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  30. Depletion of the tumor microenvironment as a novel strategy potentiating the efficacy of immunotherapies.

    Call: OPUS 23 , Panel: NZ6

    Principal investigator: dr Małgorzata Agnieszka Bajor

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  31. Intrinsic tumour radiosensitivity as a marker of chemoradiotherapy-induced immunogenic effects in rectal cancer

    Call: PRELUDIUM 21 , Panel: NZ5

    Principal investigator: Zuzanna Maria Nowicka

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  32. Use of comparative oncology approach to dissect the PD-1 intrinsic signalling in osteosarcoma. Can dog be the key for ne...

    Call: PRELUDIUM 21 , Panel: NZ1

    Principal investigator: Katarzyna Joanna Dziubek

    Uniwersytet Gdański, Międzynarodowe Centrum Badań nad Szczepionkami Przeciwnowotworowymi

  33. Investigation of the role of complement in shaping resistance to NK-cell cytotoxicity

    Call: PRELUDIUM 21 , Panel: NZ6

    Principal investigator: Aleksandra Maria Kusowska

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  34. Photoswitchable and chimeric molecules for spatially restricted and endoplasmic reticulum-specific blockade of PD-L1 pro...

    Call: SONATA BIS 11 , Panel: NZ7

    Principal investigator: dr Łukasz Dariusz Skalniak

    Uniwersytet Jagielloński, Wydział Chemii

  35. Extracellular vesicles carrying microRNA in experimental immunotherapy for glioblastoma

    Call: OPUS 21 , Panel: NZ6

    Principal investigator: dr Jakub Godlewski

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  36. Extracellular vesicles modified ex vivo as an anti-cancer immune-response boosting vaccine

    Call: PRELUDIUM 20 , Panel: NZ6

    Principal investigator: Klaudia Elżbieta Kiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  37. The SAR analysis and synthesis of complex, small molecule PD-1/PD-L1 interaction antagonists

    Call: PRELUDIUM 20 , Panel: ST4

    Principal investigator: Magdalena Maria Żarnik

    Uniwersytet Jagielloński, Wydział Chemii

  38. Molecular and cellular landscape of pulmonary and hepatic metastases of colorectal cancer with potential clinical implic...

    Call: PRELUDIUM 20 , Panel: NZ4

    Principal investigator: dr Marta Aleksandra Popęda

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  39. The clinical significance of immunosuppression in ovarian cancer microenvironments

    Call: PRELUDIUM 20 , Panel: NZ6

    Principal investigator: dr Anna Maria Pawłowska-Łachut

    Uniwersytet Medyczny w Lublinie

  40. Mechanisms of interaction between phage-derived 'dark matter' and mammalian host immunity

    Call: SHENG 2 , Panel: NZ7

    Principal investigator: prof. Krystyna Dąbrowska

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

  41. Comprehensive characterization of tumor immune contexture changes induced by cytotoxic agents in non-small cell lung can...

    Call: PRELUDIUM BIS 2 , Panel: NZ5

    Principal investigator: prof. Wojciech Maksymilian Fendler

    Uniwersytet Medyczny w Łodzi

  42. Modulation of immune cells activity in the tumor microenvironment by oligonucleotide therapeutics delivered by silk nano...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: prof. Hanna Dams-Kozłowska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  43. Increasing the precision of chimeric antigen receptor (CAR)-mediated anticancer immunotherapy by using the chemokine-ind...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny

  44. Photodynamic therapy combined with PD-1/PD-L1 blockade immunotherapy: new possibilities for the treatment of immunogenic...

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: dr hab. Janusz Marcin Dąbrowski

    Uniwersytet Jagielloński, Wydział Chemii

  45. Tyrosine-modified polyethylenimine polymers as a promising vectors for siRNA delivery in synergistic cancer immunotherap...

    Call: PRELUDIUM 19 , Panel: NZ5

    Principal investigator: Małgorzata Kubczak

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  46. Effect of immunomodulation on the pathogenesis of endometriosis in experimental models

    Call: OPUS 18 , Panel: NZ6

    Principal investigator: prof. Andrzej Adam Mackiewicz

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  47. Analysis of the effectiveness of glioblastoma immunotherapy using gamma-delta T cells

    Call: OPUS 18 , Panel: NZ6

    Principal investigator: dr hab. Grzegorz Jacek Chodaczek

    Wrocławskie Centrum Badań EIT+ Sp. z o.o.

  48. Improving therapeutic efficacy of anti-CD20 antibodies in precursor B-cell acute lymphoblastic leukemia

    Call: OPUS 18 , Panel: NZ5

    Principal investigator: dr Małgorzata Firczuk

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  49. Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies

    Call: SONATA 15 , Panel: NZ6

    Principal investigator: dr Agnieszka Graczyk-Jarzynka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  50. Modulation of exosome production to support anti-cancer treatment

    Call: OPUS 18 , Panel: NZ7

    Principal investigator: dr Liliana Monika Czernek

    Centrum Badań Molekularnych i Makromolekularnych PAN